Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alx Oncology Holdings (ALXO) Invested Capital (2019 - 2026)

Alx Oncology Holdings' Invested Capital history spans 5 years, with the latest figure at $189.7 million for Q4 2023.

  • On a quarterly basis, Invested Capital fell 28.44% to $189.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $189.7 million, a 28.44% decrease, with the full-year FY2023 number at $189.7 million, down 28.44% from a year prior.
  • Invested Capital hit $189.7 million in Q4 2023 for Alx Oncology Holdings, up from $168.8 million in the prior quarter.
  • Over the last five years, Invested Capital for ALXO hit a ceiling of $429.8 million in Q4 2020 and a floor of -$78.4 million in Q2 2020.
  • Historically, Invested Capital has averaged $208.0 million across 5 years, with a median of $258.0 million in 2020.
  • Biggest five-year swings in Invested Capital: soared 708.51% in 2020 and later crashed 41.75% in 2023.
  • Tracing ALXO's Invested Capital over 5 years: stood at -$70.6 million in 2019, then soared by 708.51% to $429.8 million in 2020, then decreased by 15.16% to $364.7 million in 2021, then decreased by 27.3% to $265.1 million in 2022, then decreased by 28.44% to $189.7 million in 2023.
  • Business Quant data shows Invested Capital for ALXO at $189.7 million in Q4 2023, $168.8 million in Q3 2023, and $212.7 million in Q2 2023.